Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens

Journal of Immunology

Volumn 176, Issue 3, 2006, Pages 1776-1783

  Duverger, Alexandra ^a   Jackson, Raymond J ^a   Van Ginkel, Frederick W ^a,e   Fischer, Romy ^a   Tafaro, Angela ^a   Leppla, Stephen H ^c   Fujihashi, Kohtaro ^a,b   Kiyono, Hiroshi ^b,d   McGhee, Jerry R ^a   Boyaka, Prosper N ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANTHRAX EDEMA TOXIN; ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; CD4 ANTIGEN; CELL RECEPTOR; CHOLERA TOXIN; CYTOKINE; EDEMA FACTOR; ENTEROTOXIN; GAMMA INTERFERON; GANGLIOSIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; NEUTRALIZING ANTIBODY; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BACILLUS ANTHRACIS; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME SUBUNIT; FEMALE; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; SALIVA; TARGET CELL; TH2 CELL; VAGINA;

EID: 31144460027     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.3.1776     Document Type: Article

References (64)

1. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55: 647-644.
2. Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19: 45-70.
3. Moayeri, M., and S. H. Leppla. 2004. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 7: 19-24.
4. Bradley, K. A., J. Mogridge, M. Mourez, R. J. Collier, and J. A. Young. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414: 225-229.
5. Scobie, H. M., G. J. Rainey, K. A. Bradley, and J. A. Young. 2003. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 100: 5170-5174.
6. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79: 3162-3166.
7. Guo, Q., Y. Shen, N. L. Zhukovskaya, J. Florian, and W. J. Tang. 2004. Structural and kinetic analyses of the interaction of anthrax adenylyl cyclase toxin with reaction products cAMP and pyrophosphate. J. Biol. Chem. 279: 29427-29435.
8. Shen, Y., N. L. Zhukovskaya, Q. Guo, J. Florian, and W. J. Tang. 2005. Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J. 24: 929-941.
9. Singh, Y., S. H. Leppla, R. Bhatnagar, and A. M. Friedlander. 1989. Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells. J. Biol. Chem. 264: 11099-11102.
10. Friedlander, A. M., R. Bhatnagar, S. H. Leppla, L. Johnson, and Y. Singh. 1993. Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect. Immun. 61: 245-252.
11. Hanna, P. C., D. Acosta, and R. J. Collier. 1993. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA 90: 10198-10201.
12. Agrawal, A., J. Lingappa, S. H. Leppla, S. Agrawal, A. Jabbar, C. Quinn, and B. Pulendran. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329-334.
13. Ballard, J. D., R. J. Collier, and M. N. Starnbach. 1996. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. Proc. Natl. Acad. Sci. USA 93: 12531-12534.
14. Goletz, T. J., K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. USA 94: 12059-12064.
15. Brassier, P., M. Weber-Levy, M. Mock, and J. C. Sirard. 2000. Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis. Infect. Immun. 68: 5731-5734.
16. Lu, Y., R. Friedman, N. Kushner, A. Doling, L. Thomas, N. Touzjian, M. Starnbach, and J. Lieberman. 2000. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proc. Natl. Acad. Sci. USA 97: 8027-8032.
17. Kushner, N., D. Zhang, N. Touzjian, M. Essex, J. Lieberman, and Y. Lu. 2003. A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen. Proc. Natl. Acad. Sci. USA 100: 6652-6657.
18. Price, B. M., A. L. Liner, S. Park, S. H. Leppla, A. Mateczun, and D. R. Galloway. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69: 4509-4515.
19. Kumar, P., N. Ahuja, and R. Bhatnagar. 2002. Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect. Immun. 70: 4997-5007.
20. Paccani, S. R., F. Tonello, R. Ghittoni, M. Natale, L. Muraro, M. M. D'Elios, W. J. Tang, C. Montecucco, and C. T. Baldari. 2005. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 201: 325-331.
21. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56: 622-647.
22. Gill, D. M. 1976. The arrangement of subunits in cholera toxin. Biochemistry 15: 1242-1248.
23. Gill, D. M., J. D. Clements, D. C. Robertson, and R. A. Finkelstein. 1981. Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect. Immun. 33: 677-682.
24. Heyningen, S. V. 1974. Cholera toxin: interaction of subunits with ganglioside GM1. Science 183: 656-657.
25. Holmgren, J., M. Lindblad, P. Fredman, L. Svennerholm, and H. Myrvold. 1985. Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine. Gastroenterology 89: 27-35.
26. Griffiths, S. L., R. A. Finkelstein, and D. R. Critchley. 1986. Characterization of the receptor for cholera toxin and Escherichia coli heat-labile toxin in rabbit intestinal brush borders. Biochem. J. 238: 313-322.
27. Fukuta, S., J. L. Magnani, E. M. Twiddy, R. K. Holmes, and V. Ginsburg. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56: 1748-1753.
28. Couch, R. B. 2004. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 350: 860-861.
29. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903.
30. van Ginkel, F. W., R. J. Jackson, Y. Yuki, and J. R. McGhee. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165: 4778-4782.
31. Eriksson, A. M., K. M. Schon, and N. Y. Lycke. 2004. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173: 3310-3319.
32. Ramirez, D. M., S. H. Leppla, R. Schneerson, and J. Shiloach. 2002. Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J. Ind. Microbiol. Biotechnol. 28: 232-238.
33. Cooksey, B. A., G. C. Sampey, J. L. Pierre, X. Zhang, J. D. Karwoski, G. H. Choi, and M. W. Laird. 2004. Production of biologically active Bacillus anthracis edema factor in Escherichia coli. Biotechnol. Prog. 20: 1651-1659.
34. Boyaka, P. N., M. Ohmura, K. Fujihashi, T. Koga, M. Yamamoto, M. N. Kweon, Y. Takeda, R. J. Jackson, H. Kiyono, Y. Yuki, and J. R. McGhee. 2003. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J. Immunol. 170: 454-462.
35. Boyaka, P. N., A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170: 5636-5643.
36. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
37. Lillard, J. W., Jr., U. P. Singh, P. N. Boyaka, S. Singh, D. D. Taub, and J. R. McGhee. 2003. MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity. Blood 101: 807-814.
38. Boyaka, P. N., M. Marinaro, R. J. Jackson, S. Menon, H. Kiyono, E. Jirillo, and J. R. McGhee. 1999. IL-12 is an effective adjuvant for induction of mucosal immunity. J. Immunol. 162: 122-128.
39. T) method. Methods 25: 402-408.
40. Elson, C. O., and W. Ealding. 1984. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 133: 2892-2897.
41. Elson, C. O., and W. Ealding. 1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132: 2736-2741.
42. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6: 269-277.
43. Elson, C. O., and M. T. Dertzbaugh. 1999. Mucosal adjuvants. In Mucosal Immunology. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee, eds. Academic Press, San Diego, pp. 817-838.
44. Bromander, A. K., M. Kjerrulf, J. Holmgren, and N. Lycke. 1993. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand. J. Immunol. 37: 452-458.
45. Cong, Y., C. T. Weaver, and C. O. Elson. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159: 5301-5308.
46. Yamamoto, M., H. Kiyono, M. N. Kweon, S. Yamamoto, K. Fujihashi, H. Kurazono, K. Imaoka, H. Bluethmann, I. Takahashi, Y. Takeda, et al. 2000. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses. J. Infect. Dis. 182: 180-190.
47. Agren, L. C., L. Ekman, B. Lowenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158: 3936-3946.
48. Agren, L., E. Sverremark, L. Ekman, K. Schon, B. Lowenadler, C. Fernandez, and N. Lycke. 2000. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving antiapoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164: 6276-6286.
49. Bonuccelli, G., F. Sotgia, P. G. Frank, T. M. Williams, C. J. de Almeida, H. B. Tanowitz, P. E. Scherer, K. A. Hotchkiss, B. I. Terman, B. Rollman, et al. 2005. Anthrax toxin receptor (ATR/TEM8) is highly expressed in epithelial cells lining the toxin's three sites of entry (lung, skin, and intestine). Am. J. Physiol. 288: C1402-C1410.
50. Beauregard, K. E., S. Wimer-Mackin, R. J. Collier, and W. I. Lencer. 1999. Anthrax toxin entry into polarized epithelial cells. Infect. Immun. 67: 3026-3030.
51. Doling, A. M., J. D. Ballard, H. Shen, K. M. Krishna, R. Ahmed, R. J. Collier, and M. N. Starnbach. 1999. Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Infect. Immun. 67: 3290-3296.
52. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, et al. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155: 4621-4629.
53. Vajdy, M., M. H. Kosco-Vilbois, M. Kopf, G. Kohler, and N. Lycke. 1995. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 181: 41-53.
54. Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173: 627-635.
55. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect. Immun. 64: 1516-1525.
56. Kweon, M. N., M. Yamamoto, F. Watanabe, S. Tamura, F. W. Van Ginkel, A. Miyauchi, H. Takagi, Y. Takeda, T. Hamabata, K. Fujihashi, et al. 2002. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J. Infect. Dis. 186: 1261-1269.
57. Agren, L. C., L. Ekman, B. Lowenadler, J. G. Nedrud, and N. Y. Lycke. 1999. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162: 2432-2440.
58. Lycke, N., A. K. Bromander, L. Ekman, U. Karlsson, and J. Holmgren. 1989. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J. Immunol. 142: 20-27.
59. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146: 2908-2914.
60. McGee, D. W., C. O. Elson, and J. R. McGhee. 1993. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect. Immun. 61: 4637-4644.
61. Staats, H. F., and F. A. Ennis, Jr. 1999. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J. Immunol. 162: 6141-6147.
62. Gagliardi, M. C., F. Sallusto, M. Marinaro, S. Vendetti, A. Riccomi, and M. T. De Magistris. 2002. Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses. Int. J. Med. Microbiol. 291: 571-575.
63. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, K. Fujihashi, F. W. Van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94: 5267-5272.
64. Sharma, M., H. Khanna, N. Arora, and Y. Singh. 2000. Anthrax toxin-mediated delivery of cholera toxin-A subunit into the cytosol of mammalian cells. Biotechnol. Appl. Biochem. 32(Pt. 1): 69-72.